Loading this company
Edwards Lifesciences Corporation
EWPrices in USD
TickerWorth ScoreC51/100
What we think
Priced above our range of $26.62 to $49.95.
Price
$86.60USD down −$1.50 (−1.70%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$26.62–$49.95
What the price needs: revenue growth of more than 25%/yr for 5 years (our model assumes 7.2%), or investors accepting a ~5.2% discount rate, vs the 9.1% our model uses.
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $86.60Priced · Prices are delayed.
Is it a good business?
- Valuation17 out of 100
- Growth67 out of 100
- Financial health100 out of 100
- Past performance83 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$101.81 across 26 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. It operates in the Medical Devices industry (Healthcare sector), headquartered in United States. The company employs roughly 16,000 people.
Key stats
52-week range$74.43–$96.29
- Open
- $88.21
- Day high
- $88.40
- Day low
- $86.09
- Previous close
- $88.10
- Volume
- 4,007,412 · 1.08× avg
- Average volume
- 3,715,746
- Market cap
- $49,864,278,016.00
- P/E (TTM)
- 51.55
- Earnings per share
- $1.68
- Beta
- 0.86
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Changed leadership or its board
- Reported quarterly or annual results
- Changed leadership or its board
- Changed leadership or its board
- Reported quarterly or annual results
- Reported quarterly or annual results
- Issued a public disclosure (Reg FD)
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Lippis Daniel J.Option exercise · $44,988.92
- Lippis Daniel J.Open-market sale ·
Not investment advice. TickerWorth Score is a model output.